Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Significant Drop in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 13,300 shares, a drop of 50.9% from the December 15th total of 27,100 shares. Based on an average daily volume of 652,600 shares, the short-interest ratio is currently 0.0 days. Approximately 2.4% of the company’s shares are short sold.

Bluejay Diagnostics Trading Up 3.3 %

Shares of NASDAQ BJDX traded up $0.11 during trading hours on Wednesday, hitting $3.47. 19,623 shares of the company traded hands, compared to its average volume of 84,280. The company’s 50 day moving average price is $4.05 and its 200 day moving average price is $10.79. Bluejay Diagnostics has a 12 month low of $3.03 and a 12 month high of $419.64. The stock has a market capitalization of $1.92 million, a price-to-earnings ratio of 0.00 and a beta of 0.48.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. CVI Holdings LLC purchased a new stake in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 66,165 shares of the company’s stock, valued at approximately $46,000. CVI Holdings LLC owned about 19.69% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is owned by hedge funds and other institutional investors.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.